Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

NCT05735327 ·Status: ACTIVE_NOT_RECRUITING

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NCT03609918 ·Status: COMPLETED

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

NCT01648517 ·Status: COMPLETED ·Phase: PHASE2

Asia Pacific and Russia Diagnostic Study for EGFR Testing

NCT01788163 ·Status: COMPLETED ·Phase: NA

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).

NCT02321046 ·Status: COMPLETED

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

NCT02834936 ·Status: COMPLETED ·Phase: PHASE2

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

NCT06858410 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Stage III NSCLC RWE in Chinese Patients

NCT04023812 ·Status: COMPLETED

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 ·Status: RECRUITING ·Phase: PHASE2

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

NCT02588261 ·Status: TERMINATED ·Phase: PHASE3

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05863325 ·Status: RECRUITING ·Phase: PHASE2

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

NCT00085839 ·Status: COMPLETED ·Phase: PHASE2

Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC

NCT04629027 ·Status: UNKNOWN

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

NCT06282874 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

NCT04031898 ·Status: COMPLETED

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NCT06465238 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer

NCT01407822 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

NCT00600587 ·Status: COMPLETED ·Phase: PHASE2

Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)

NCT00568841 ·Status: UNKNOWN ·Phase: PHASE2

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02296125 ·Status: COMPLETED ·Phase: PHASE3

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

NCT02006043 ·Status: UNKNOWN ·Phase: PHASE2